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Pancreatic cancer is the fourth leading cause of cancer death in the United
States and the 5-year survival rate is only 5% to 10%. There are only a few
non-specific symptoms associated with the early stage cancer, therefore most
patients are diagnosed in a late stage. Due to the lack of effective treatments
on pancreatic cancer and the fact that the early stage has a 39% 5-year sur-
vival rate, the biggest hope to control this disease is early detection. Therefore,
discovery of effective and reliable non-invasive biomarkers for early detection
of pancreatic cancer has been a major topic in the research field. Very re-
cently, exosomal microRNAs have become promising candidates of diagnos-
tic markers due to the facts that 1) such small non-coding RNA are stably
present in the tissue and can get into blood circulation via exosome packag-
ing which protects them from enzymatic degradation; 2) cancer cells, even at
their early stages, may secrete up to tenfold more exosomes than normal cells
and some disease-associated microRNAs can get into blood stream; 3) circu-
lating exosomal microRNAs may carry early signals of cancers. With the goal
to facilitate cancer detection, in this study, we have developed an integrated
computational approach that leverages advanced genomics and bioinformat-
ics to identify exosomal microRNAs that can be promising early detection
biomarkers in pancreatic cancer. First, we have analyzed large-scale small
RNA microarray data collected from the GEO database to identify microRNA
candidates that are differentially-expressed in cancer versus healthy control.
Then we have explored several classification models to identify the most ef-
fective signature of microRNAs that can well differentiate cancer from normal
based on the expression profiles. Through a series of comparisons and val-
idations, the support vector machine-based classifier has achieved the best
performance among all. A combination of five significantly-expressed microR-
NAs (hsa-miR-125a-3p, hsa-miR-6893-5p, hsa-miR-125b-1-3p, hsa-miR-6075,
and hsa-miR-4294) achieved the best accuracy and AUC of 97.6% and 99.7%,
respectively, which is highly promising. In order to explore the molecular de-
terminants in microRNA secretion to further guide the non-invasive biomarker
detection in the blood stream, in the second part of this project, we focused on
sequence analysis of exosomal microRNAs for motif detection. Particularly, a
graph-based motif-finding algorithm previously developed in our lab has been
applied for this purpose. As a result, the motif [CUG][AU]G[UG] was found
highly enriched in microRNAs associated with cancer exosomes. Knowing such
properties is highly useful to guide a more targeted search in contrast to the
profiling-based discovery where most of the detected microRNAs are highly
abundant but likely disease irrelevant. In summary, our study has presented a
new data-driven strategy that can potentially advance the biomedical research
in biomarker discovery. Particularly, we have demonstrated that circulating
exosomal microRNAs can be used as promising stable non-invasive biomarkers
for early diagnosis of pancreatic cancer.
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The biggest challenge in treating cancer is that most cancers are not detected
in the early stage, and due to evolution cancers advance in later stage when no
effective treatment options are available. Therefore, early detection of cancer
is the key to effective treatments for cancer patients [14]. Pancreatic cancer
is an aggressive lethal disease in which cancer cells form in the tissues of the
pancreas. The pancreas is located deep in the body and is surrounded by many
crucial organs (Figure 1.1). The pancreas has two main functions, releasing
enzymes that help food digestion and producing hormones that manage blood
sugar levels. The digestive enzymes are made by exocrine pancreas cells and
the hormones are made by neuroendocrine pancreas cells. Pancreatic cancer
is classified into two types based on which part of the pancreas is affected [26].
Most pancreatic cancers arise in exocrine cells which make digestive enzymes.
This cancer type is called pancreatic adenocarcinoma (PAAD) and is often
found at an advanced stage [2]. The less common pancreas cancer type is
formed in the hormone producing cells. This type of cancer is called pancreatic
neuroendocrine tumors or pancreatic endocrine cancer and it usually has a
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better prognosis. Pancreatic cancer is relatively rare, but it is the deadliest
one. It is seldomly diagnosed early because there are few symptoms in early
stages [14]. Pancreatic cancer does not cause symptoms until advanced stages
when it has already spread to other organs. In addition, the symptoms of
pancreatic cancer are similar to many other illnesses which make it hard to
diagnose [9, 14].
Figure 1.1: Anatomy of the pancreas [9]
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1.2 Motivation
1.2.1 Challenges in early detection of pancreatic cancer
There are no biomarkers currently available for early diagnosis of pancreatic
cancer. As a broad tumor biomarker, carbohydrate antigen 19-9 (CA19-9)
is current used as a biomarker for pancreatic cancer in clinical practice [11].
However, CA19-9 is not specific to pancreatic cancer and it is not sensitive
enough for early diagnosis of pancreatic cancer [26]. At the time of diagnosis,
many patients have already reached advanced stage cancer [14]. In addition,
pancreas is located deep in the body and surrounded by many organs, getting
a tissue biopsy is a complex and risky task. Therefore, new biomarkers present
in liquid biopsy, with high sensitivity and high specificity, are urgently needed
for early detection of pancreatic cancer.
1.2.2 Roles of circulating exosomal microRNAs in early cancer de-
tection
Exosomes can be isolated from multiple body fluids including blood plasma,
serum, urine, breast milk, and saliva. Exosomes contain an abundance of
small molecules (proteins, DNA, RNAs, etc.) which are pivotal in the cell-to-
cell communication. It is believed that cancer cells secrete more exosomes than
normal cells because they use exosomes as a mean of transportion for small
molecules which needs to be spread to cultivate microenvironments for future
metastasis [11]. Exosomes can regulate cell proliferation, invasion, metasta-
sis, and participate in formation of chemoresistance in cancer treatment [14].
Many studies have indicated that proteins, microRNA, and mRNA enriched
in exosomes are great candidates for biomarker cancer research regarding early
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cancer diagnosis and determination of prognosis [3].
Among all the components in the exosomal cargos, exosomal microRNAs have
been frequently reported to be the most promising biomarker candidates [26].
microRNAs play a key role in up and down regulation of pathways related
to cancer development, tumorigenesis, metastasis, and resistance to various
therapies. Many tumor-cell-released exosome-derived microRNAs are proan-
giogenic factors that promote neovascularization and metastasis. Exosomes
are mean of transportation for transferring microRNAs from donor cells to
target recipient cells, leading to reprogramming of the recipient cells. Exo-
somal microRNAs are more stable than free microRNAs because exosomes
protect microRNAs from degradation by RNAase. Therefore, exosome is an
enriched stable source of microRNAs in body fluids.
One of the challenges in developing microRNAs as biomarkers is the heteroge-
nous nature of circulating microRNAs. microRNAs isolated from circulation
have various forms including protein bound microRNAs and exosome associ-
ated microRNAs. The expression profile of microRNAs in exosomes is dif-
ferent from that in other microenvironment, suggesting that a strict sorting
mechanism exists. Selective isolation of circulating microRNAs released from
pancreatic cancer cells is a crucial step in the development of microRNAs as
biomarkers. Since cancer cells release tenfold more exosomes than normal
cells and certain microRNAs are selectively enriched in exosomes of cancer
cells compared to exosomes of normal cells, circulating exosomal microRNAs
are likely enriched in cancer-derived microRNAs [26]. Exosomes released by
tumor cells likely contain microRNA biomarkers which can be used to predict
5
the presence of tumors in cancer patients. Opposite to tissue-based biopsy
for cancer detection, liquid biopsies is less invasive, easier to collect, and less
expensive. Therefore, circulating exosomal microRNAs are valuable biomark-
ers for early detection of cancer and biomarker research based on circulating
exosomal microRNAs is an expending field [3].
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Chapter 2
Background and Related Work
2.1 Background about microRNAs and exosomes
2.1.1 microRNA formation and function
microRNAs are small single-stranded, non-coding RNA molecules with an av-
erage of 22 nucleotides in length [16, 20]. There are four steps in microRNA
formation (Figure 2.1). In the first step, microRNA gene is transcribed to
generate a primary microRNA. Then primary microRNA is cleaved to form
a precursor microRNA which is then exported into the cytoplasm. In the
cytoplasm, precursor microRNA is undergone further cleavage to remove the
stem loop and form a short double-stranded microRNA molecule called a du-
plex. Finally, the duplex unwinds to release one strand. The remaining strand
combines with some proteins and forms a RNA-induced Silencing Complex
(RISC). The RISC binds target mRNA to prevent protein production by one
of two distinct gene silencing mechanisms. In the first mechanism, RISC just
simply cuts the mRNA which will be further destroyed by the cell. The other
mechanism is the translation repression in which the RISC prevents ribosome
subunits from binding, thus, prevents translation from happening. Either way,
mature microRNAs can regulate gene expression levels and control many pro-
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cesses in the cells.
Cancer is a type of genetic disease in which abnormal cells grow uncontrollably
by disregarding the normal rules of cell division. The failure in gene regula-
tion involving in cell proliferation, differentiation and apoptosis is associated
with cancer initiation and progression [16]. microRNAs play a crucial role
in regulating genes that control these processes. Therefore, dysregulation of
microRNA expression profiles can lead to cancer development.
2.1.2 Exosome formation and function
Exosomes are nanometer-sized (30-100 nm in diameter) membrane-derived
lipid bilayer vesicles that contain constituents (proteins, lipids, and nucleic
acids like DNA, mRNA, microRNA, etc.) of the cell that secrete them (Figure
2.2). Exosomes are the smallest extracellular vesicles.
Exosome formation is divided into five different stages (Figure 2.3): (A) Ex-
osome is derived from early endosome formed from plasma membrane. (B)
Early endosome becomes late endosomes. (C) Then forms early multivesic-
ular bodies. (D) Late multivesicular bodies. (E) Late multivesicular bodies
can either get degraded by lysosomes or fuse with the membrane to release
exosomes [3]. Released exosomes can be taken by surrounding recipient cells
(via fusion or receptor-ligand interaction) or travel through biological fluids
(blood, urine, saliva) and later taken up by distant cells. Exosomes can be
isolated from multiple body fluids such as blood plasma, serum, urine, breast
milk, and saliva [14]. Molecules being packed in exosomes are not random se-
lected. There are motif sequences that determine if some molecules are being
packed or not.
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Figure 2.1: microRNA formation and function [16]
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Figure 2.2: The structure and content of exosome [3]
Exosomes are important in intercellular communication because of their abil-
ity in transferring information from donor cells to recipient cells, leading to
changes in the recipient cells. Cancer cells produce about tenfold more ex-
osomes than normal healthy cells. Exosomes are extremely stable, and the
contents packed in exosomes are valuable resources for biomarker research for
early detection of cancer [14, 26, 3].
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Figure 2.3: The formation and releasing of exosome [3]
2.2 Literature review on exosomal microRNAs as biomark-
ers for pancreatic cancer
The difference of microRNA expression between pancreatic cancer cells and
normal healthy cells can be used to identify biomarkers for diagnostic and
prognostic purposes. Expression of several microRNAs was elevated in the
circulation of pancreatic cancer patients and several exosomal microRNAs have
been reported as potential biomarkers [26]. The expression profiles of miR-17-
5p and miR-21 were greatly enhanced in pancreatic cancer patients compared
to patients with benign pancreatic diseases and healthy controls [14, 26]. Using
the NGS technology and qRT-PCR, miR-10b, miR-550, miR-196a, miR-1246,
11
and miR-451a were determined to be present at higher levels in exosomes
extracted from pancreatic cancer cells. Serum exosomal microRNAs, including
miR-1246, miR-4644, miR-3976 and miR-4306, were significantly upregulated
in patients with pancreatic cancer compared to patients with benign pancreatic
disorders [26]. Table 2.1 summarized microRNAs which were identified as
biomarkers in pancreatic cancer patients. These results suggest that some
exosomal microRNAs can be used as potential liquid biopsy biomarkers for
early diagnosis of pancreatic cancer [14].
Biomarkers Samples Comments Refs
miR-2, miR-
155
27 PDACs and 8 CPs These exosomal microRNAs
isolated from pancreatic juice
were shown as promising





12 PCs (6 males, 6 fe-
males), 13 healthy par-
ticipants
miR-1246 and miR-4644 in
salivary exosomes could be
useful biomarkers for identifi-














451a and miR-21 levels were
upregulated in PVB, thus,




22 PCs, 6 benign pan-
creatic tumors, 7 am-
pullary carcinomas, 6
CPs, 8 healthy controls
Diagnostic biomarker for di-
viding PC and non-PC
[21, 14,
1]
miR-10b 3 PDACs, 3 CPs, 3
healthy controls
Diagnostic biomarker for





15 PDACs (Stage I-
IIA), 15 healthy con-
trols
Diagnostic biomarker for di-
viding PDAC and non-PC.
Plasma exosome miR-196a
and miR-1246 levels were sig-
nificantly elevated in pancre-
atic cancer patients as com-








20 healthy donors, 131
pancreatic cancer, 25
CP, 22 benign pancre-
atic tumors, 12 non
pancreatic cancer
These biomarkers were sig-
nificantly upregulated in pa-
tients with pancreatic cancer
when compared to patients
with benign pancreatic disor-
ders. The authors suggested
to use a combination of pro-
tein and microRNA biomark-
ers.
[18]
miR-451a 7 PDACs with stage I,
43 PDACs with stage II,
20 healthy controls
Minimally invasive biomarker
for the prediction of recur-







29 PDACs, 11 CPs High expression of miR-10b,
miR-21, miR-30c, and miR-
181a and low expression of
miR-let7a is a better indica-
tor of pancreatic cancer than





32 PCs, 29 IPMNs, 22
controls
The level of these microRNAs
was significantly elevated in
patients with pancreatic can-
cer and intraductal papillary
mucinous neoplasm as com-







63 PCs, 63 control sub-
jects
Identify biomarkers for pan-






24 PCs, 21 healthy con-
trols, 10 biliary tract
cancer patients
Distinguishable patterns be-
tween cancer patients and
healthy controls. However,
they were unable to distin-
guish pancreatic cancer from
biliary tract cancer
[10]
Table 2.1: microRNAs as biomarkers for early diagnosis of pancreatic cancer.
PC stands for pancreatic cancer; PDAC stands for pancreatic ductal adeno-
carcinoma; CP stands for chronic pancreatitis; IPMN stands for intraductal
papillary mucinous neoplasm.
The above studies suggested that exosomal microRNAs have great promise as
biomarkers in the diagnosis and prognosis of pancreatic cancer. However, most
studies have been conducted with a small number of samples and the results
vary between studies. Each study suggests different circulating microRNAs
as biomarkers for pancreatic cancer. Research projects at larger scales and
better designs are needed to better identify potential biomarkers for cancer
detection and improve their reproducibility. More efforts should be given to




Our goal is to develop an approach for identifying promising non-invasive ex-
osomal microRNA biomarkers for early diagnosis and prognosis of pancreatic
cancer.
3.1 Research question 1
What exosomal microRNAs can be used as potential non-invasive biomarkers
for the detection of pancreatic cancer?
3.2 Research question 2
What are the motif sequences in exosomal microRNAs that make these mi-





4.1.1 Dataset 1: Microarray expression data on pancreatic cancer
vs normal
We downloaded the microRNA expression profile of Series GSE59856 from
the NCBI Gene Expression Omnibus (GEO) database using R script. This
publicly available microarray data consist of 100 pancreatic cancer patients
(pancreatic ductal adenocarcinoma) and 150 healthy controls (Figure 4.1).
As described in the NCBI GEO Series GSE59856, total RNAs were isolated
from serum samples using 3D-gene RNA extraction reagent. Comprehensive
microRNA expression profiles were captured using a 3D-Gene microRNA la-
beling kit, a highly sensitive microarray. The downloaded data contain 103
missing values (NaN, Not a Number). We replaced each NaN with the average
of five values just before it. The data table contained accession number (e.g.,
MIMAT0000062) instead of the name of microRNA (e.g., hsa-let-7a-5p). To
make it easier to understand, we used Pandas dataframe in Jupyter Notebook
to replace all accession numbers by their corresponding microRNA names be-
fore moving forward with further data analysis.
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Figure 4.1: Number of samples in GSE59856 (pancreatic cancer: ”1” and
healthy control: ”0”)
4.1.2 Dataset 2: Exosomal miRNA sequences from ExoCarta database
We downloaded exosomal microRNA data from ExoCarta, an exosome database
which provide with the contents that were identified in exosomes in multiple
organisms. We selected only exosomal microRNAs which were found in human
(Homo sapiens). We used fastaselect.pl ([4]) to extract the sequences of these
microRNAs from the miRBase database v22 ([12]). As a result, 880 sequences
were obtained for human exosomal microRNAs in the ExoCarta database.
4.2 Data analysis for Series GSE59856
4.2.1 Visualization of sample distributions in 2-D and 3-D
In this microRNA dataset, we have a total of 250 samples (150 healthy con-
trols and 100 cancer samples) and 2555 features (microRNAs). The number of
samples are much smaller than the number of features. This is a common big
18
p little n problem in microRNA datasets. We cannot see sample distribution
in 2555 dimensions. Therefore, we performed Principal Component Analy-
sis (PCA) for feature extraction so that we can see sample distributions in
two- and three-dimensions. Normal healthy samples were labeled as “0” and
pancreatic cancer samples were labeled as “1”.
4.2.2 Building Machine Learning Models for Cancer Classification
In this research, machine learning models for binary classification of the pan-
creatic cancer versus healthy control were built and evaluated using Scikit-
learn, a software machine learning library for Python. The following algo-
rithms were chosen to be examined: SVM, decision tree classifier, linear dis-
criminant analysis, quadratic discriminant analysis, and Gaussian naive bayes.
The SVM algorithm has been widely applied in the biological sciences as a
means of classifier for molecular data [29]. Decision tree classifier is one of
the common machine learning methods to address the challenging task, large
dimensionality and very small number of samples, of gene expression data
classification [7]. Linear discriminant analysis is among the most effective
procedures in the domain of high-dimensional prediction [8]. Quadratic dis-
criminant analysis is also capable of handling with high dimensional data [2].
Gaussian naive bayes is naturally immune to the curse of dimensionality [25].
Data were splited into training samples and testing samples with a test size of
33%. The performance of the above models was evaluated using cross valida-
tion and some standardized evaluation metrics such as recall, precision, and
F1 score.
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4.2.3 Differential gene expression analysis using Limma
For microarray data Series GSE59856, we used Limma (R script, Biocon-
ductor) to identify the microRNAs which were expressed differently in the
exosomes of pancreatic patients and healthy donors. Limma stands for linear
models for microarray data since it was historically designed to analyze mi-
croarray data. Quantile normalization was conducted to normalize the signals
across the different microarrays tested. The level of differential gene expression
was ranked based on B-statistics which was the same order with t-statistics in
this case.
4.2.4 SVM-based models for cancer classification
Even though we have 2555 microRNAs in the dataset, not all microRNAs
are equally important in distinguishing cancer samples from normal samples.
Strongly differentially expressed microRNAs are likely the best biomarkers to
separate these two groups. Here we built a SVM model for binary classification
of cancer patients from healthy controls.
In order to see how many top differently express microRNAs are needed to
differentiate pancreatic cancer patients from healthy controls, full microRNA
profiles, top 20 differently expressed microRNAs, top 15 differently expressed
microRNAs, top 10 differently expressed microRNAs, top 5 differently ex-
pressed microRNAs, and top 2 differently expressed microRNAs were used as
input for the SVM model. We compared the performance of the SVM model
when different numbers of microRNAs were used as inputs by using some stan-
dardized evaluation metrics such as precision, recall, F1 score, and confusion
20
Figure 4.2: Schematic flowchart for motif detection [5]
matrix. Candidate biomarkers were chosen based on microRNAs which were
differentially expressed in pancreatic cancer patients and healthy controls.
4.3 Find motifs associated with exosomes (ExoCarta)
In order to explore the molecular determinants in microRNA secretion to fur-
ther guide the non-invasive biomarker detection in the blood stream, in the
second part of this project, we focused on sequence analysis of exosomal mi-
croRNAs for motif detection. Particularly, a graph-based motif-finding algo-
rithm previously developed in our lab [5] has been applied for this purpose.
The computational procedure for motif detection is shown in Figure 4.2. For
details, please refer to the original paper ”A systematic approach to RNA-




5.1 Visualization of GSE59856 dataset in 2-D and 3-D
Non-invasive screening methods for the early detection of pancreatic cancer
is urgently needed. In this study, we investigated the microRNA expression
profiles of 100 pancreatic cancer patients and 150 healthy controls (GSE59856,
microarray data). Principal component analysis (PCA) was used to visualize
sample distribution in two- and three-dimensional scatter plots which reveal
separate clusters between the pancreatic cancer and healthy control groups. As
shown in Figures 5.1 and 5.2, the overall differentially expressed microRNAs
can be used to distinguish cancer samples from healthy controls, except for
one outlier which is healthy control.
5.2 Building Machine Learning Models for Cancer Clas-
sification
As shown in Table 5.1, Support Vector Machine (SVM), and decision tree clas-
sifier (DTC) models performed well. Precision, recall, F1 score, and accuracy
reach almost 1 in these cases. On the other hand, linear discriminant anal-
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Figure 5.1: Data visualization for GSE59856 in 2-dimension. Yellow: cancer,
blue: healthy controls
ysis (LDA), and Gaussian naive bayes (NB), quadratic discriminant analysis
(QDA) performed badly. These model could not distinguish cancer samples
from normal samples. All standardized evaluation metrics including precision,
recall, F1 score, accuracy and area under curve are low. We chose SVM for
further analysis because SVM has the highest performance in term of recall.
In addition, SVM is well known to be a simple and effective approach.
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Figure 5.2: Data visualization for GSE59856 in 3-dimension. Yellow: cancer,
blue: healthy controls
Model Recall Precision F1 score Accuracy AUC
SVM 0.963 0.962 0.959 0.959 0.998
Decision Tree Classifier 0.952 0.964 0.953 0.954 0.952
Linear Discriminant 0.714 0.713 0.717 0.732 0.704
Gaussian Naive Bayes 0.579 0.594 0.577 0.599 0.580
Quadratic Discriminant 0.495 0.448 0.388 0.443 0.569
Table 5.1: Machine Learning Algorithm Comparison
5.3 Candidate biomarkers for detection of pancreatic
cancer
We conducted an extensive analysis of publicly available microRNA expression
data (GSE59856) to identify candidate exosomal microRNAs associated with
pancreatic cancer. A comprehensive list of microRNAs which were differen-
tially expressed between cancer samples and controls is shown in Table A.1.
It is believed that cancer cells secrete more exosomes than healthy cells to
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cultivate new microenvironments for future metastasis. However, we did not
observe this phenomenon in our analysis. Table 5.2 shows the top 20 differen-
tially expressed microRNAs. Among these, 5 microRNAs were up-regulated
and 15 were down-regulated in pancreatic cancer. The expression signals of
the 4 most significant microRNAs are showed in Figure 5.3. Among those mi-
croRNAs, hsa-miR-125a-3p, hsa-miR-6893-5p, and hsa-miR-125b-1-3p were
down-regulated in cancer samples while hsa-miR-6075 was up-regulated. The
functions of the down-regulated microRNAs could be cancer/tumor suppres-
sion. Not having enough these microRNAs could lead to out-of-control can-
cer/tumor growth. Consistent with the discovery of Kojima et. al. 2015
[11], hsa-miR-125a-3p was found to be the best biomarker for the detection of
pancreatic cancer.
We built a SVM model for the classification of pancreatic cancer from healthy
control. The effectiveness of the model when combining multiple significant
microRNA biomarkers are shown in Table 5.3. When hsa-miR-125a-3p was
used as the single biomarker, 28 of 33 (84.85%) pancreatic cancer samples
were identified (Table 5.3). When using a combination of the top 5 microRNA
biomarkers, the recall rate (true positive divide by the total of true positive
and false negative) increased significantly to 96.97%. That means only one out
of 33 cancer samples was mistakenly identified as normal sample. With the
combination of the top 15 differentially expressed microRNAs, all cancer sam-
ples were correctly identified (recall rate = 1). We found that the combination
of the full microRNA profile (2555 microRNAs) did not yield the best results
(Table 5.3). The reason is that not every microRNA is equally important in
distinguishing cancer samples from healthy controls and the presence of ir-
25
microRNA logFC adj.P.Val P.Value t B
hsa-miR-125a-3p -2.46 3.11E-71 1.22E-74 -26.55 159.23
hsa-miR-6893-5p -1.35 8.27E-64 6.47E-67 -24.05 141.66
hsa-miR-125b-1-3p -1.62 8.92E-53 1.05E-55 -20.59 116.12
hsa-miR-6075 1.03 9.87E-49 1.55E-51 19.34 106.61
hsa-miR-4294 -1.02 9.60E-44 1.88E-46 -17.84 95.00
hsa-miR-204-3p -1.62 3.32E-42 7.79E-45 -17.37 91.31
hsa-miR-1469 0.55 4.38E-42 1.20E-44 17.31 90.88
hsa-miR-575 -1.40 1.14E-39 3.58E-42 -16.59 85.23
hsa-miR-6729-5p 0.25 6.25E-37 2.20E-39 15.78 78.86
hsa-miR-4476 -1.56 5.37E-36 2.10E-38 -15.50 76.62
hsa-miR-6820-5p -0.72 3.11E-35 1.34E-37 -15.26 74.79
hsa-miR-6765-3p -1.23 5.03E-32 2.36E-34 -14.32 67.37
hsa-miR-150-3p -0.98 3.68E-31 1.87E-33 -14.06 65.32
hsa-miR-4792 1.08 1.15E-29 6.28E-32 13.61 61.84
hsa-miR-6836-3p 0.61 2.88E-29 1.69E-31 13.49 60.85
hsa-miR-6799-5p -0.41 1.14E-28 7.17E-31 -13.30 59.42
hsa-miR-4450 -1.45 8.23E-28 5.47E-30 -13.04 57.41
hsa-miR-4470 -0.95 1.43E-27 1.01E-29 -12.96 56.80
hsa-miR-4419a -0.98 5.66E-27 4.21E-29 -12.78 55.38
hsa-miR-4530 -0.71 5.87E-27 4.59E-29 -12.77 55.30
Table 5.2: Top 20 circulating microRNA biomarkers that differentiated cancer
patients from healthy controls
relevant or partially relevant microRNAs can interfere with cancer diagnosis.
To balance the amount of work and the effectiveness of diagnosis methods,
the five most significant differentially expressed microRNAs (hsa-miR-125a-
3p, hsa-miR-6893-5p, hsa-miR-125b-1-3p, hsa-miR-6075, and hsa-miR-4294)
should be used. By using a combination of these five microRNA biomark-
ers, we were able to distinguish pancreatic cancer patients from those who
were healthy, with a diagnostic accuracy of 97.59% and an AUC of 99.70%.
For a better performance, a combination of the top 15 microRNAs or top 20
microRNAs should be used for cancer detection.
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Figure 5.3: Expression signals of the top 4 differentially expressed microRNAs
in cancer and healthy control. The error bars are standard deviations.
5.4 microRNAmotif sequences associated with exosomes
Motif sequence analysis is important in understanding of microRNA loading
mechanism. Previous experimental validation in our laboratory on selected
microRNAs in colon cancer cell line showed that mutant of motif sequence
shows lowered abundance of exosomal microRNAs compared to the wildtype,
which indicates that the motif region is responsible for microRNA loading
and packaging [5]. The mechanistic knowledge discovery is the primary goal
for motif analysis. In the meantime, although not ideally, we can use motif
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Biomarker Recall F-1 score Accuracy AUC ROC
Top 1 microRNA 0.848 0.918 0.940 0.998
Top 2 microRNAs 0.879 0.935 0.952 0.997
Top 5 microRNAs 0.970 0.970 0.976 0.997
Top 10 microRNAs 0.939 0.969 0.976 0.999
Top 15 microRNAs 1.000 1.000 1.000 1.000
Top 20 microRNAs 1.000 1.000 1.000 1.000
2555 microRNAs 1.000 0.985 0.988 0.999
Table 5.3: The effectiveness of the SVM model for differentiation of cancer
samples from healthy controls with different biomarkers.
information to screen for potential secreted microRNA candidates.
Predicted motif sequences highly enriched in exosomal microRNAs are shown
in Figure 5.4 and Table 5.4. The higher the information content (IC) and
coverage, the more likely that the sequences are true motif sequences.
Figure 5.4: Motifs highly enriched in microRNAs associated with exosomes
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Motif sequence Coverage (in 880) Information Content P value
[CUG][AU]G[UG] 716 1.34 1.34e-48
[AU][CUG][UG]G 715 1.35 9.14e-47
C[AU][UG][AUG] 714 1.36 1.88e-38
[UG]G[CU][ACU] 713 1.34 2.67e-37
[CUG][CG][AU]G 694 1.35 5.57e-37
Table 5.4: Motif sequences associated with exosomal microRNAs
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Chapter 6
Conclusions and Future work
Pancreatic cancer is a deadly disease because it is usually not diagnosed until
late stages when treatments are less effective. It is difficult to perform invasive
method for the diagnosis of this cancer because of the anatomical position of
the pancreas. Therefore, development of non-invasive reliable biomarkers is
greatly needed. In this study, we have explored several classification models
that can well differentiate cancer from normal based on the expression pro-
files. Through a series of comparisons and validations, the support vector
machine-based classifier has achieved the best performance among all. Using
Limma, we identified microRNA candidate biomarkers that were differentially-
expressed in cancers versus healthy control. A combination of five significantly-
expressed microRNAs (hsa-miR-125a-3p, hsa-miR-6893-5p, hsa-miR-125b-1-
3p, hsa-miR-6075, and hsa-miR-4294) achieved the best accuracy and AUC
of 97.6% and 99.7%, respectively, which is highly promising. In order to ex-
plore the molecular determinants in microRNA secretion to further guide the
non-invasive biomarker detection in the blood stream, we focused on sequence
analysis of exosomal microRNAs for motif detection. MDS2, a graph-based
motif-finding algorithm, was used and the motif [CUG][AU]G[UG] was found
highly enriched in microRNAs associated with cancer exosomes. Our research
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has further demonstrated that circulating exosomal microRNAs are potential
non-invasive biomarkers for early detection of pancreatic cancer. However,
more studies including wet laboratory experiments should be conducted to
validate the role of these exosomal microRNAs as biomarkers for pancreatic
cancer. In addition, research at a large scale should be conducted in this area
to discover reliable biomarkers for early detection of pancreatic cancer.
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Appendix A
Appendix: Differential Gene Expression
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miRNA_ID miRNA_ID_LIST logFC adj.P.Val P.Value t B
MIMAT0004602 hsa-miR-125a-3p -2.46265 3.11E-71 1.22E-74 -26.5514983 159.2336447
MIMAT0027686 hsa-miR-6893-5p -1.35424 8.27E-64 6.47E-67 -24.0476507 141.660934
MIMAT0004592 hsa-miR-125b-1-3p -1.62010667 8.92E-53 1.05E-55 -20.5872088 116.1176164
MIMAT0023700 hsa-miR-6075 1.02857 9.87E-49 1.55E-51 19.34110758 106.6070716
MIMAT0016849 hsa-miR-4294 -1.02188 9.60E-44 1.88E-46 -17.8426717 95.00093014
MIMAT0022693 hsa-miR-204-3p -1.62281 3.32E-42 7.79E-45 -17.3695698 91.30658797
MIMAT0007347 hsa-miR-1469 0.55154667 4.38E-42 1.20E-44 17.31480761 90.87823522
MIMAT0003240 hsa-miR-575 -1.40042333 1.14E-39 3.58E-42 -16.5939509 85.22833314
MIMAT0027359 hsa-miR-6729-5p 0.24522333 6.25E-37 2.20E-39 15.78344707 78.85929303
MIMAT0019003 hsa-miR-4476 -1.55749 5.37E-36 2.10E-38 -15.4988512 76.62148221
MIMAT0027540 hsa-miR-6820-5p -0.71875 3.11E-35 1.34E-37 -15.2653905 74.78605461
MIMAT0027431 hsa-miR-6765-3p -1.22388 5.03E-32 2.36E-34 -14.3205532 67.37029305
MIMAT0004610 hsa-miR-150-3p -0.97852667 3.68E-31 1.87E-33 -14.058088 65.31671554
MIMAT0019964 hsa-miR-4792 1.07801 1.15E-29 6.28E-32 13.61183115 61.83516557
MIMAT0027575 hsa-miR-6836-3p 0.60857667 2.88E-29 1.69E-31 13.48579308 60.85459911
MIMAT0027498 hsa-miR-6799-5p -0.40789333 1.14E-28 7.17E-31 -13.3012223 59.4211691
MIMAT0018971 hsa-miR-4450 -1.45381333 8.23E-28 5.47E-30 -13.0409565 57.40548771
MIMAT0018997 hsa-miR-4470 -0.95412333 1.43E-27 1.01E-29 -12.9629568 56.80279842
MIMAT0018931 hsa-miR-4419a -0.97691 5.66E-27 4.21E-29 -12.778823 55.38279795
MIMAT0019069 hsa-miR-4530 -0.71462667 5.87E-27 4.59E-29 -12.7676884 55.29706019
MIMAT0004804 hsa-miR-615-5p -0.74105 9.10E-27 7.48E-29 -12.7048968 54.81384506
MIMAT0027574 hsa-miR-6836-5p 0.87229667 1.14E-26 9.86E-29 12.66927799 54.53995997
MIMAT0018976 hsa-miR-4454 -0.78388242 2.31E-26 2.08E-28 -12.5795445 53.80078635
MIMAT0029782 hsa-miR-7641 -1.41821 2.62E-26 2.47E-28 -12.5509869 53.63156223
MIMAT0022945 hsa-miR-1236-5p -1.02696333 2.75E-26 2.69E-28 -12.5397781 53.54558254
MIMAT0027654 hsa-miR-6877-5p -0.44874333 5.21E-26 5.30E-28 -12.4519032 52.87211244
MIMAT0004952 hsa-miR-665 0.65543667 5.33E-26 5.64E-28 12.44405472 52.81201439
MIMAT0004748 hsa-miR-423-5p -0.82222667 6.51E-26 7.14E-28 -12.4134904 52.57805713
MIMAT0000093 hsa-miR-93-5p -1.07547 7.55E-26 8.57E-28 -12.3897228 52.39621706
MIMAT0031000 hsa-miR-8073 0.69370333 2.70E-25 3.18E-27 12.21982677 51.09880009
MIMAT0018192 hsa-miR-3918 -0.85064859 5.67E-25 6.88E-27 -12.1253292 50.33392442
MIMAT0027660 hsa-miR-6880-5p -0.75192333 2.60E-24 3.26E-26 -11.9162029 48.79139197
MIMAT0000070 hsa-miR-17-5p -1.09597333 6.43E-24 8.31E-26 -11.7937119 47.864895
MIMAT0027478 hsa-miR-6789-5p 0.35199 8.09E-24 1.08E-25 11.75961507 47.60746691
MIMAT0005586 hsa-miR-1231 0.53994667 1.05E-23 1.44E-25 11.72185772 47.32264744
MIMAT0026720 hsa-miR-887-5p -0.75318667 4.17E-23 5.88E-25 -11.5362133 45.92611982
MIMAT0019691 hsa-miR-4634 0.27832667 4.94E-23 7.15E-25 11.5103661 45.73220601
MIMAT0022286 hsa-miR-5585-3p 0.95149667 9.67E-22 1.44E-23 11.11207871 42.76141096
MIMAT0031178 hsa-miR-7975 -0.73372667 1.13E-21 1.72E-23 -11.0881434 42.5839632
MIMAT0000103 hsa-miR-106a-5p -1.07524667 2.68E-21 4.20E-23 -10.9687763 41.70095295
MIMAT0018179 hsa-miR-3907 -0.90884333 1.16E-20 1.86E-22 -10.768419 40.22632732
MIMAT0019737 hsa-miR-4664-5p -0.79173899 3.51E-20 5.77E-22 -10.6196998 39.10940092
MIMAT0031180 hsa-miR-7977 -0.69807 3.52E-20 5.92E-22 -10.6120279 39.08213336
MIMAT0023710 hsa-miR-6085 -0.26914 4.48E-20 7.72E-22 -10.576027 38.81962316
MIMAT0019715 hsa-miR-4651 -0.32729 1.29E-19 2.27E-21 -10.4292844 37.75313003
MIMAT0031016 hsa-miR-8089 -0.4462 2.76E-19 4.97E-21 -10.3220415 36.97738248
MIMAT0015070 hsa-miR-3188 0.44487667 3.51E-19 6.46E-21 10.28607223 36.71790883
MIMAT0003228 hsa-miR-564 -1.11032333 3.95E-19 7.42E-21 -10.2671031 36.58121623
MIMAT0019859 hsa-miR-4734 0.27697 4.27E-19 8.19E-21 10.25352186 36.48341149
MIMAT0020601 hsa-miR-1273f 0.70575667 7.01E-19 1.37E-20 10.18251803 35.97293508
Table A.1: Differentially expressed microRNAs between pancreatic cancer
samples and healthy controls
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